Cancer combination therapies utilizing a nicotinamide phosphoribosyltransferase inhibitor in combination with a nicotinamide adenine dinucleotide salvage pathway precursor

A method of treating a cancer in a subject comprising

• determining that the cancer's nicotinamide adenine dinucleotide (NAD) salvage pathway is unavailable by detecting that the cancer is NMRKlow and Mychigh;
• and
• based on the determining,
• administering a therapeutically effective amount of a nicotinamide phosphoribosyltransferase (NAMPT) inhibitor and an external factor to the subject, wherein
• the NAMPT inhibitor is selected from the group consisting of FK866 ((E)-N-[4-(1-benzoyl-4-yl)-butyl]-3-(pyridin-3-yl) acrylamide), CHS-828 (N-[6-(4-chlorophenoxy)hexyl]-N′-cyano-N″-4-pyridinyl-guanidine, GNE-617 (N-(4-((3,5-difluorophenyl)sulfonyl)benzyl)imidazo[1,2-a]pyridine-6-carboxamide), GNE-618 (N-[[4-[[3-(Trifluoromethyl)phenyl]sulfonyl]phenyl]methyl]-1H-pyrazolo [3,4-b] pyridine-5-carboxamide), STF118804 (4-[5-Methyl-4-[((4-methylphenyl)sulfonyl]methyl]-2-oxazolyl]-N-(3pyridinylmethyl)benzamide), KPT-9274 ((E)-3-(6-aminopyridin-3-yl)-N-[[5-[4-(4,4-difluoropiperidine-1-carbonyl)phenyl]-7-(4-fluorophenyl)-1-benzofuran-2-yl]methyl]prop-2-enamide), and LSN3154567 (2-hydroxy-2-methyl-N-[1,2,3,4-tetrahydro-2-[2-(3-pyridinyl oxy)acetyl]-6-isoquinolinyl]-1-propane-sulfonamide, and
• the external factor is selected from the group consisting of nicotinamide mononucleotide (NMN), nicotinamide riboside (NR), reduced NR (NRH), nicotinic acid riboside (NAR), reduced nicotinic acid ribo side (NARH), NR chloride, 1-(2′,3′,5′-triacetyl-beta-D-ribofuranosyl)-1,4-dihydronicotinic acid, 1-(2′,3′,5′-triacetyl-beta-D-ribofuranosyl)-1,4-nicotinamide, O-ethyl NR (OENR), tri-O-acetyl O′-ethyl NR (TAENR), N-dimethyl NR (DMNR), N-allyl NR (ANR), NRH triacetate, NRH triproprionate, NRH tributyrate, NRH triisobutyrate, NR+ tripentanoate, NR+ trihexanoate, NRH triethylcarbonate, NRH tribenzoate, NR+ monohexanoate, NRH monodecanoate, NRH monotetradecanoate, Nic mononucleotide (NMN), NR+ monooleate, NR+ monohexanoate, NR+ monononanoate, NR+ monododecanoate, NR+ monopentanoate, and NR+ monoundecanoate
• thereby treating cancer in the subject.